Group 1 - Riel Group's shares have been suspended from trading since December 1, 2025, due to concerns raised by auditors regarding related payments, leading to the establishment of an independent investigation committee [1] - The company has delayed the publication of its 2025 interim results and report, highlighting the importance of compliance and governance in listed companies [1] - The investigation's outcome remains uncertain, raising market concerns and emphasizing the need for strict adherence to governance standards in the industry [1] Group 2 - Aotai Biotech plans to repurchase its shares using 100 million to 200 million RMB of funds raised from its initial public offering, with a buyback price not exceeding 85 RMB per share [2] - This move reflects the company's confidence in its value and aims to enhance shareholder returns by reducing registered capital through share cancellation [2] - The buyback initiative is seen as a positive response to market conditions and aims to boost investor confidence [2] Group 3 - Yibai Pharmaceutical expects a net loss attributable to shareholders of 285 million to 342 million RMB for 2025, with a projected revenue decline of 14% due to decreased sales of its main products [3] - Despite a forecasted 18% reduction in costs, expenses are still expected to exceed revenue, leading to continued losses [3] - The company plans to recognize goodwill impairment of 110 million to 132 million RMB, further exacerbating its financial challenges [3] Group 4 - Heng Rui Medicine has received approval for clinical trials of two drugs, SHR-7787 and Abedilizumab, from the National Medical Products Administration [4] - The approval underscores the company's strength in innovative drug development and enhances its product pipeline in the oncology sector [4] - The advancement of these clinical trials is expected to solidify Heng Rui's position in the industry and contribute to the growth of cancer treatment options [4]

Core Viewpoint - The innovative drug sector is expected to experience a resurgence in 2025, transitioning from a broad market rally to a focus on select stocks driven by global clinical data, overseas commercialization, and domestic profitability turning points [1] Group 1: Market Performance - In 2025, the A-share innovative drug index saw an annual increase of nearly 20%, while the H-share index rose by 66.52%. The first half of the year recorded increases of approximately 17% for A-shares and 58% for H-shares, with the second half showing more modest gains of about 3% and 9% respectively [1] - The A-share billion-dollar club includes companies like BeiGene (市值4190.64亿元), Hengrui Medicine (市值3994.27亿元), and Baillie Gifford (市值1332.18亿元), while the H-share club includes Hengrui Medicine (市值4729.34亿元), BeiGene (市值3191亿元), and others [2] Group 2: Company Dynamics - Companies in the billion-dollar club are valued based on "pipeline value + BD monetization + global sales peak." Capital markets are comparing these firms to global leaders, elevating them from "First-in-class" to "Best-in-class" [3] - In 2025, domestic innovative drug license-out transactions totaled 83, amounting to $84.5 billion, surpassing the total of over $60 billion for 2024. Hengrui Medicine's international deals included partners like GSK and Merck, with upfront payments totaling $765 million [3] Group 3: Market Challenges - Some companies that previously entered the billion-dollar club, such as Kintor Pharmaceutical and China National Pharmaceutical Group, have fallen below the threshold due to systemic valuation corrections and stricter FDA approval standards [4] - The market has become desensitized to BD transactions, as evidenced by the stock price drop of Innovent Biologics following a $11.4 billion collaboration announcement, indicating a tightening of valuation expectations [4] Group 4: Capital Operations - As the innovative drug market heats up in 2025, companies are initiating new capital operations, including acquisitions and cross-border listings. For instance, China National Pharmaceutical Group acquired Lixian Pharmaceuticals for approximately $500 million [5] - Baillie Gifford raised 3.764 billion yuan through a private placement in the A-share market, while also applying for an IPO in Hong Kong [5] Group 5: Small-cap Stocks - The top three performing innovative drug stocks in A-shares for 2025 were Shuyou Pharmaceutical (涨幅488%), Yipinhong (涨幅370%), and Yifang Biotechnology (涨幅235%). In H-shares, the top performers were Beihai Kangcheng (涨幅1824%), Heber Pharmaceuticals (涨幅553%), and Sanofi (涨幅311.18%) [7] - These stocks have core products that received high recognition, with clinical pipelines achieving significant breakthroughs, such as Shuyou's STSP-0601 and Beihai Kangcheng's Selinexor [7] Group 6: Future Outlook - The innovative drug sector is expected to enter a "hardcore alpha" phase in 2026, focusing on companies that can deliver genuine clinical data, achieve overseas commercialization, and demonstrate domestic profitability [10] - The emphasis will shift from broad market rallies to specific companies that can prove their clinical trial results and secure sales milestones, with a focus on high-demand areas like dual antibodies and ADCs [11][12]

电子行业主力资金净流入金额居首。 A股主要指数今日（1月21日 ）集体收涨，行业板块涨多跌少，贵金属、能源金属、采掘行业、电机、 半导体、小金属、电子元件等板块涨幅居前，煤炭、酿酒、商业百货、电网设备等板块跌幅居前。 从今日主力资金情况来看，沪深两市全天主力资金净流入56.08亿元。17个行业主力资金净流入，电 子、有色金属、银行、机械设备行业主力资金净流入金额分别为52.2亿元、43.76亿元、21.59亿元、 11.36亿元；非银金融、通信、计算机、交通运输等行业主力资金净流入金额均超5亿元。 14个主力资金净流出行业中，电力设备、国防军工、传媒行业主力资金净流出金额居前，分别为44.51 亿元、28.47亿元、11.42亿元； 农林牧渔、食品饮料、家用电器、商贸零售行业主力资金净流出金额均 超6亿元。 10股获主力资金净流入均超5亿元 从个股看，56股主力资金净流入均超2亿元，10股获主力资金净流入均超5亿元。 中国长城主力资金净流入14.27亿元，居首。公司近日发布业绩预告，2025年度归母净利润亏损收窄至 3500万元至7000万元，同比减亏95.27%至97.63%，显著改善；扣非净利润亏损6.3 ...

盘后数据出炉。 1月21日，A股市场整体上涨。截至收盘，上证指数报4116.94点，上涨0.08%；深证成指报14255.13点，上涨0.7%；创业板指数报3295.52点，上涨0.54%； 北证50指数上涨0.14%。 1.A股市场主力资金净流入56.08亿元 今日A股市场主力资金开盘净流出41.97亿元，尾盘净流入6.26亿元，A股市场全天主力资金净流入56.08亿元。 | | | 沪深两市近五日主力资金流向情况(亿元) | | | | --- | --- | --- | --- | --- | | 日期 | | | 净流入金额 开盘净流入 尾盘净流入 超大单净买入 | | | 2026-1-21 | 56. 08 | -41.97 | 6.26 | 154. 57 | | 2026-1-20 | -764. 07 | -221.93 | -61.61 | -471.97 | | 2026-1-19 | -397.98 | -162.72 | -58. 29 | -209.12 | | 2026-1-16 | -238.85 | -106. 45 | -38. 37 | -133.83 | | 2026- ...

盘后数据出炉。 1月21日，A股市场整体上涨。截至收盘，上证指数报4116.94点，上涨0.08%；深证成指报14255.13点，上涨0.7%；创业板指数报3295.52点，上涨0.54%； 北证50指数上涨0.14%。 1.A股市场主力资金净流入56.08亿元 今日A股市场主力资金开盘净流出41.97亿元，尾盘净流入6.26亿元，A股市场全天主力资金净流入56.08亿元。 | | | 沪深两市近五日主力资金流向情况(亿元) | | | | --- | --- | --- | --- | --- | | 日期 | | | 净流入金额 开盘净流入 尾盘净流入 超大单净买入 | | | 2026-1-21 | 56. 08 | -41.97 | 6.26 | 154. 57 | | 2026-1-20 | -764. 07 | -221.93 | -61. 61 | -471.97 | | 2026-1-19 | -397.98 | -162.72 | -58. 29 | -209.12 | | 2026-1-16 | -238.85 | -106. 45 | -38. 37 | -133.83 | | 2026 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of SHR-7787 injection and Adebeli monoclonal antibody injection, indicating progress in its oncology pipeline [1][2] Group 1: SHR-7787 Injection - SHR-7787 injection is a Class 1 therapeutic biological product designed to activate T cells to target and kill tumor cells [1] - The total research and development investment for SHR-7787 injection has reached approximately 54.1 million yuan (unaudited) [1] Group 2: Adebeli Monoclonal Antibody Injection - Adebeli monoclonal antibody injection is a humanized anti-PD-L1 monoclonal antibody that reactivates the immune system's anti-tumor activity by blocking the PD-1/PD-L1 pathway [2] - The product was approved for market in 2023 for first-line treatment of extensive-stage small cell lung cancer in combination with carboplatin and etoposide [2] - Global sales of similar products Atezolizumab, Avelumab, and Durvalumab are projected to total approximately 9.648 billion USD in 2024 [2] - The total research and development investment for Adebeli monoclonal antibody injection has reached approximately 1.101 billion yuan (unaudited) [2]

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of SHR-7787 injection and Adebali monoclonal antibody injection, indicating progress in its oncology pipeline [1][2] Group 1: SHR-7787 Injection - SHR-7787 injection is a Class 1 therapeutic biological product that activates T cells to target and kill tumor cells [1] - The total R&D investment for SHR-7787 injection has reached approximately 54.1 million yuan (unaudited) [1] Group 2: Adebali Monoclonal Antibody Injection - Adebali monoclonal antibody injection is a humanized anti-PD-L1 monoclonal antibody that reactivates the immune system's anti-tumor activity by blocking the PD-1/PD-L1 pathway [2] - The injection was approved for market in 2023 for first-line treatment of extensive-stage small cell lung cancer in combination with carboplatin and etoposide [2] - The total R&D investment for Adebali monoclonal antibody injection has reached approximately 1.101 billion yuan (unaudited) [2] - Global sales of similar products Atezolizumab, Avelumab, and Durvalumab are projected to total approximately 9.648 billion USD in 2024 [2]

Group 1 - Company subsidiary Shanghai Hengrui Medicine Co., Ltd. and Shanghai Shengdi Medicine Co., Ltd. received approval from the National Medical Products Administration for clinical trials of SHR-7787 injection and Adebeli monoclonal antibody injection [1] - SHR-7787 injection is a Class 1 therapeutic biological product that activates T cells to target and kill tumor cells, with a cumulative R&D investment of approximately 54.1 million yuan (unaudited) [1] Group 2 - Adebeli monoclonal antibody injection is a humanized anti-PD-L1 monoclonal antibody that blocks the PD-1/PD-L1 pathway to reactivate the immune system's anti-tumor activity, approved for first-line treatment of extensive-stage small cell lung cancer in combination with carboplatin and etoposide [2] - The global sales of similar products Atezolizumab, Avelumab, and Durvalumab are projected to reach approximately 9.648 billion USD in 2024, with Atezolizumab and Durvalumab already approved for sale in China [2] - The cumulative R&D investment for Adebeli monoclonal antibody injection is approximately 1.101 billion yuan (unaudited) [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2026年1月21日 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2026-01 ...

Core Viewpoint - The article highlights the significant progress in the global weight loss and metabolic drug sector, particularly focusing on Roche's initiation of the Phase III clinical trial for its dual agonist RO7795068, marking a critical phase in the competitive landscape of GLP-1/GIP dual-target therapies [6][10]. Group 1: Clinical Development - Roche has officially launched the first Phase III clinical trial for RO7795068, a dual GLP-1R/GIPR agonist, involving approximately 1,600 participants, indicating a decisive step in the GLP-1 compound target field [6]. - The trial aims to validate the early efficacy observed in previous studies, with a primary endpoint of percentage change in body weight from baseline at 72 weeks, while also assessing long-term safety and tolerability [8]. Group 2: Efficacy and Competitive Landscape - Early clinical data for RO7795068 shows promising results, with a 24-week treatment leading to an average weight loss of 18.8% in non-diabetic obese or overweight participants, and a 100% response rate for weight loss exceeding 5% [8]. - In the diabetic obese or overweight population, RO7795068 demonstrated a 3.0 percentage point reduction in HbA1c and an 8.6% weight loss after 12 weeks, indicating its potential to compete with existing products in both weight management and glycemic control [8]. Group 3: Market Positioning - The competitive landscape for Phase III candidates includes various companies, such as Hengrui Medicine and Eli Lilly, indicating a shift from exploratory phases to a race for market leadership in the GLP-1/GIP dual-target space [9]. - Roche's entry into this market is significant due to its established capabilities in clinical development and long-term safety management, which may provide an advantage in balancing efficacy, tolerability, and adherence in a market projected to be worth trillions [9][10].